var data={"title":"Paricalcitol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Paricalcitol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6725?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=paricalcitol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Paricalcitol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=paricalcitol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Paricalcitol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206463\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zemplar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206464\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zemplar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206482\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vitamin D Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206466\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In stage 3 to 5 CKD maintain  Ca x P &lt;55 mg<sup>2</sup>/dL<sup>2</sup>, reduce or interrupt dosing if recommended calcium phosphorus product (Ca x P) is exceeded or hypercalcemia is observed (K/DOQI Clinical Practice Guidelines, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism associated with chronic renal failure (stage 5 CKD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.04 to 0.1 mcg/kg (2.8 to 7 mcg) given as a bolus dose no more frequently than every other day at any time during dialysis; dose may be increased by 2 to 4 mcg every 2 to 4 weeks; doses as high as 0.24 mcg/kg (16.8 mcg) have been administered safely;  the dose of paricalcitol should be adjusted based on serum intact  PTH (iPTH) levels, as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Same or increasing iPTH level: Increase paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH level decreased by &lt;30%: Increase paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH level decreased by &gt;30% and &lt;60%: Maintain paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH level decrease by &gt;60%: Decrease paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH level 1.5 to 3 times upper limit of normal: Maintain paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial dose is calculated, in mcg, based on baseline iPTH level divided by 80 and administered 3 times weekly, no more frequently than every other day. <b>Note:</b> To reduce the risk of hypercalcemia initiate only after baseline serum calcium has been adjusted to &le;9.5 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Titration dose (mcg) = Most recent iPTH level (pg/mL) divided by 80</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> In situations where monitoring of iPTH, calcium, and phosphorus occurs less frequently than once per week, a more modest initial and dose titration rate may be warranted:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Modest titration dose (mcg) = Most recent iPTH level (pg/mL) divided by 100</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment for elevated serum calcium:</i> Decrease dose by 2 to 4 mcg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Secondary hyperparathyroidism associated with stage 3 and 4 CKD:</b> Adults: Oral: Initial dose based on baseline serum iPTH:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">iPTH &le;500 pg/mL: 1 mcg once daily or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">iPTH &gt;500 pg/mL: 2 mcg once daily or 4 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <i>Dosage adjustment based on iPTH level relative to baseline</i>, adjust dose at 2- to 4-week intervals:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH same or increased: Increase paricalcitol dose by 1 mcg once daily or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH decreased by &lt;30%: Increase paricalcitol dose by 1 mcg once daily or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH decreased by &ge;30% and &le;60%: Maintain paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH decreased by &gt;60%: Decrease paricalcitol dose by 1 mcg once daily* or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">iPTH &lt;60 pg/mL: Decrease paricalcitol dose by 1 mcg once daily* or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">*If patient is taking 1 mcg once daily and further dose reduction is needed, decrease to 1 mcg 3 times/week. If further dose reduction is required, withhold therapy as needed and restart at a lower dosing frequency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206476\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=paricalcitol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Paricalcitol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism associated with chronic renal failure (stage 5 CKD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Children &ge;5 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Children &ge;10 to Adolescents &le;16 years: Initial dose is calculated, in mcg, based on baseline iPTH level divided by 120 (round down to the nearest whole number) and administered 3 times/week, no more frequently than every other day; every 4 weeks may increase each administered dose by 1 mcg (eg, increase from 1 mcg 3 times/week to 2 mcg 3 times/week) to maintain iPTH within target range. At any time, each administered dose may be decreased by 2 mcg. If dosage reduction is required while receiving 2 mcg 3 times/week or 1 mcg 3 times/week, discontinue therapy, resuming when appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism associated with stage 3 and 4 CKD:</b> Oral: Children &ge;10 to Adolescents &le;16 years: Initial: 1 mcg 3 times/week, no more frequently than every other day; every 4 weeks may increase each administered dose by 1 mcg (eg, increase from 1 mcg 3 times/week to 2 mcg 3 times/week) to maintain iPTH within target range. At any time, each administered dose may be decreased by 1 mcg. If dosage reduction is required while receiving 1 mcg 3 times/week, discontinue therapy, resuming when appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206467\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206468\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206469\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206452\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemplar: 1 mcg, 2 mcg, 4 mcg [DSC] [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mcg, 2 mcg, 4 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemplar: 2 mcg/mL (1 mL); 5 mcg/mL (1 mL, 2 mL) [contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mcg/mL (1 mL); 5 mcg/mL (1 mL, 2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206438\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730141\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with or without food. With the 3 times/week dosing schedule, doses should not be given more frequently than every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:  Administered as a bolus dose at any time during dialysis. Doses should not be administered more often than every other day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206454\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Prevention and treatment of secondary hyperparathyroidism associated with stage 5 chronic kidney disease (CKD)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Prevention and treatment in adults and pediatric patients 10 years and older with secondary hyperparathyroidism associated with stage 3 and 4 CKD and stage 5 CKD patients on hemodialysis or peritoneal dialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7297725\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound alike/look alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Paricalcitol may be confused with calcifediol, calcitriol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemplar may be confused with zaleplon, Zelapar, zolpidem, ZyPREXA Zydis</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206445\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported in adults, unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (children, adolescents, and adults: 5% to 13%), diarrhea (7% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (bacterial, fungal, viral: 3% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (children and adolescents: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (7%), edema (6% to 7%), hypotension (5%), palpitations (3%), chest pain (3%), peripheral edema (3%), syncope (3%), atrial flutter (&lt;2%), cardiac arrhythmia (&lt;2%), cerebrovascular accident (&lt;2%), chest discomfort (&lt;2%), ischemic bowel disease (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (5% to 7%), chills (5%), insomnia (5%), vertigo (5%), headache (3% to 5%), anxiety (3%), depression (3%), fatigue (3%), malaise (3%), abnormal gait (&lt;2%), agitation (&lt;2%), confusion (&lt;2%), delirium (&lt;2%), hypoesthesia (&lt;2%), myoclonus (&lt;2%), nervousness (&lt;2%), paresthesia (&lt;2%), restlessness (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4% to 6%), dermal ulcer (3%), ecchymoses (3%), acne vulgaris (&lt;2%), alopecia (&lt;2%), burning sensation of skin (&lt;2%), extravasation reactions (&lt;2%), night sweats (&lt;2%), pruritus (&lt;2%), urticaria (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypervolemia (5%), dehydration (3%), hypoglycemia (3%), hirsutism (&lt;2%), hypercalcemia (&lt;2%), hyperkalemia (&lt;2%), hyperparathyroidism (&lt;2%), hyperphosphatemia (&lt;2%), hypocalcemia (&lt;2%), hypoparathyroidism (&lt;2%), increased thirst (&lt;2%), weight loss (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (5% to 8%), gastrointestinal hemorrhage (5%), peritonitis (5%), constipation (4% to 5%), abdominal pain (4%), dyspepsia (3%), xerostomia (3%), decreased appetite (&lt;2%), dysgeusia (&lt;2%), dysphagia (&lt;2%), gastritis (&lt;2%), gastroesophageal reflux disease (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary urgency (children and adolescents: 6%), chronic renal failure (3%), uremia (3%), urinary tract infection (3%), erectile dysfunction (&lt;2%), mastalgia (&lt;2%), vaginal infection (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&lt;2%), lymphadenopathy (&lt;2%), malignant neoplasm of breast (&lt;2%), prolonged bleeding time (&lt;2%), rectal hemorrhage (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (&lt;2%), increased serum AST (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (5%), sepsis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (5%), arthritis (5%), weakness (3% to 5%), back pain (3% to 4%), leg cramps (3%), muscle spasm (3%), joint stiffness (&lt;2%), muscle twitching (&lt;2%), myalgia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (children and adolescents: 6%; adults: &lt;2%), glaucoma (&lt;2%), ocular hyperemia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (8%), asthma (children and adolescents: 6%), pneumonia (5%), oropharyngeal pain (4%), bronchitis (3%), cough (3%), sinusitis (3%), dyspnea (&lt;2%), orthopnea (&lt;2%), pulmonary edema (&lt;2%), upper respiratory tract infection (&lt;2%), wheezing (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (3% to 5%), laboratory test abnormality (&lt;2%), swelling (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema (including laryngeal edema), increased serum creatinine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206457\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to paricalcitol or any component of the formulation; vitamin D toxicity; hypercalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for vitamin D analogues is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206442\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures; chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification. Phosphate and vitamin D (and its derivatives) should be withheld during therapy to avoid hypercalcemia. Risk of hypercalcemia may be increased by concomitant use of calcium-containing supplements and/or medications that increase serum calcium (eg, thiazide diuretics).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730134\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206447\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10197&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Paricalcitol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Paricalcitol may enhance the adverse/toxic effect of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Paricalcitol. Management: Monitor clinical response to paricalcitol closely when used with orlistat. When this combination must be used, consider administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of orlistat<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206448\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730133\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617450\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if paricalcitol is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730140\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain coconut or palm kernel oil.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206450\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Signs and symptoms of vitamin D intoxication and hypercalcemia .</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium and phosphorus:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Twice weekly during initial phase, then at least monthly once dose established</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Baseline, at least every 2 weeks for initial 3 months or following dose adjustment, then monthly for 3 months, then every 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum or plasma intact PTH (iPTH):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Every 2 to 4 weeks, then every 3 months once dose established</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: : Baseline, at least every 2 weeks for 3 months or following dose adjustment, then monthly for 3 months, then every 3 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730135\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total serum calcium (K/DOQI 2003): CKD stages 3 and 4: 8.4 to 10.2 mg/dL (2.1 to 2.6 mmol/L); CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3 to 5D) (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus (K/DOQI 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stages 3 and 4: 2.7 to 4.6 mg/dL (0.87 to 1.48 mmol/L) (adults); maintain within age-appropriate limits (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 5 (including those treated with dialysis): 3.5 to 5.5 mg/dL (1.13 to 1.78 mmol/L) (children &gt;12 years and adults); 4 to 6 mg/dL (1.29 to 1.94 mmol/L) (children 1 to 12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">KDIGO guidelines recommend maintaining normal ranges for CKD stages 3 to 5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium-phosphorus product (K/DOQI 2003): CKD stage 3 to 5: &lt;55 mg<sup>2</sup>/dL<sup>2</sup> (children &gt;12 years and adults); &lt;65 mg<sup>2</sup>/dL<sup>2</sup> (children &le;12 years); <b>Note:</b> In paricalcitol injectable clinical trials involving adult CKD patients on dialysis, a serum-calcium product &lt;75 mg<sup>2</sup>/dL<sup>2 </sup>was used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0 to 5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0 to 65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0 to 6.0 pmol/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target ranges by stage of chronic kidney disease (KDIGO 2009): CKD stage 3 to 5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2 to 9 times the upper limit of normal for the assay used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206441\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreased renal conversion of vitamin D to its primary active metabolite (1,25-hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor (VDR), which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption. Paricalcitol is a synthetic vitamin D analog which binds to and activates the VDR in kidney, parathyroid gland, intestine and bone, thus reducing PTH levels and improving calcium and phosphate homeostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206456\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Healthy subjects: Oral: 34 L; IV: 24 L </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stage 3 and 4 CKD: Oral: 44 to 46 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stage 5 CKD: Oral: 38 to 49 L; IV: 31 to 35 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hydroxylation and glucuronidation via hepatic and nonhepatic enzymes, including CYP24, CYP3A4, UGT1A4; forms metabolites (at least one active) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 72% to 86% in healthy subjects</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Healthy subjects: Oral: 4 to 6 hours; IV: 5 to 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Stage 3 and 4 CKD: Oral: 17 to 20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Stage 5 CKD (on HD or PD): Oral: 14 to 18 hours; IV: 14 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 3 hours: Delayed by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Healthy subjects: Feces (oral: 70%; IV: 63%); urine (oral: 18%, IV: 19%); 51% to 59% as metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422271\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Paricalcitol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg (30): $332.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg (30): $665.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg (30): $1,330.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zemplar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg (30): $468.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg (30): $936.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Paricalcitol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg/mL (1 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/mL (1 mL): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zemplar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg/mL (1 mL): $7.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/mL (1 mL): $18.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206458\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Paricon (BD);</li>\n      <li>Paritol (BD);</li>\n      <li>Zemplar (AE, AR, AT, BB, BG, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, FI, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IT, JO, KR, KW, LT, LV, MT, MX, MY, NI, NL, NO, PA, PE, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TR, TW, UA, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease.&rdquo; Available at https://www.kidney.org/sites/default/files/docs/bone_children_nkfguideline.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 1. Evaluation of Calcium and Phosphorus Metabolism.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 3. Evaluation of Serum Phosphorus Levels.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide3.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, &quot;KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),&quot; <i>Kidney Int Suppl</i>, 2009, 76(S113):1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zemplar (paricalcitol capsules) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zemplar (paricalcitol injection) [prescribing information]. Lake Forest, IL; Hospira Inc; October 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10197 Version 146.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206463\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206464\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F206482\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206466\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F206476\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F206467\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F206468\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F206469\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206452\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206438\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F730141\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206454\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7297725\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206445\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206457\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206442\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F730134\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206447\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206448\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F730133\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617450\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F730140\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F206450\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F730135\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206441\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206456\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422271\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206458\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10197|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=paricalcitol-patient-drug-information\" class=\"drug drug_patient\">Paricalcitol: Patient drug information</a></li><li><a href=\"topic.htm?path=paricalcitol-pediatric-drug-information\" class=\"drug drug_pediatric\">Paricalcitol: Pediatric drug information</a></li></ul></div></div>","javascript":null}